Arzeda, a Protein Design Company, has entered a collaboration with Takeda aimed at deploying AI-based protein design to optimize the properties of protein biologics.
 
Takeda will leverage Arzeda’s Intelligent Protein Design Technology, which has the potential to accelerate the optimization of proteins that can be incorporated into therapeutic products. Applying the latest advances in digital biology, using computational design and machine learning algorithms, the collaboration aims to help improve therapeutic proteins in Takeda’s research pipeline.
 
“Arzeda is thrilled to collaborate with a global pharmaceutical company like Takeda to apply our AI-based protein design platform in this rapidly growing industry that stands to help address some of the significant challenges associated with drug development that could lead to transformative therapies for patients,” said Alexandre Zanghellini, Ph.D., CEO of Arzeda. “Takeda is a leader in the biopharmaceutical space, and we look forward to the ways in which this collaboration will enable our companies to build on each of our unique areas of expertise.”